World Pharmaceutical and Biopharmaceutical Market

World Pharmaceutical and Biopharmaceutical Market

2010-2015 (Pipeline Analysis of the Top 50 Companies)

What Will The Pharmaceutical Market Look Like in the Next Five Years?

This research undertaking is the result of a detailed analysis of the late stage R&D pipeline of the 50 top companies in pharmaceuticals, the companies that produce the lion's share of revenues. While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Companies such as Amgen and Genzyme, which specialize in biotechnology, are now competing with a growing number of companies and the lines between pharmaceutical and biotechnology specialty companies are becoming more blended; which is a trend expected to continue to grow.

This Kalorama Information market research report, The World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines) and providing estimates and forecasts of the world biopharma market.

Biopharma and Pharma: The Line Becomes Blurred

The line between pharmaceutical companies and biopharmaceutical companies is blurred to the point of no longer being a distinct. Among the top companies in biopharmaceuticals are, not surprisingly, the same names that have dominated pharmaceuticals for years - Pfizer, Merck and Novartis. These companies have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts. Specialist companies such as Amgen and Genzyme, now competing with a growing number of companies. The result of all interest in biological solutions to major diseases? In creased activity in the research and development departments of major pharmaceutical companies in recent years, activity that we believe will have near-term market impact.

Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses.

The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.

Key Issues and Trends in the Industry

Issues and Trends discussed in this report include:

• Biotechnology Drug Development
• Orphan Drugs
• Fast Track Drug Status
• Other Accelerated Methods for Drug Approval
• Pharmaceutical Regulatory Exclusivity
• Biosimilar Development
• Aging Populations
• Mergers, Acquisitions, and Collaborations
• Contributors to R&D Success
• R&D Spending Trends
• The Role of Contract Research Organizations
• Sustainability in a Changing Pharmaceutical Industry

Also, despite an in-depth interview process and complete review of company financials, some variation in company rankings is possible. This is more likely with privately held companies or companies where prescription pharmaceutical and biopharmaceutical sales are not discussed.

In this comprehensive look a the pipeline of major companies, Kalorama Information presents an accurate picture of the marketplace today, including

• Market Estimates by Major Drug Category, including:
  • Cardiovascular/Blood
  • Neurotherapeutics
  • Infection
  • Oncology
  • Respiratory/Inflammatory
  • Gastrointestinal
  • Other
• Discussion of Marketplace Trends
• Pipeline Analysis of Major Pharmacos
• Detailed Company Profiles
• Comparison of Market at Current Growth Versus Impact of Late-Stage Products
• Biopharmaceutical Market Breakdown
• Best-Selling Biopharmaceutical Products
• Regulatory Activity and Market Impact

Kalorama Information's market research into this topic is based on review of government filings and company literature, but also interviews with executives and experts, and the perspective of an analyst who has authored scores of reports in this industry.

Late Stage Product Development of the Top 50 Companies

50 top companies make up over 90% of the world biopharmaceutical market; The top three companies have nearly a quarter of global sales in 2009.

The top 50 companies discussed in this report include:

• Abbott
• Actelion
• Alcon, Inc.
• Allergan
• Amgen
• Astellas
• AstraZeneca
• Baxter International
• Bayer
• Biogen
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene Corp.
• Cephalon
• Chugai Pharmaceutical
• CSL
• Daiichi Sankyo
• Dainippon
• Eisai
• Eli Lilly & Co.
• Endo
• Forest
• Genzyme
• Gilead Sciences
• GlaxoSmithKline
• Hospira
• Johnson & Johnson
• Lundbeck
• Menarini
• Merck
• Merck KGaA
• Mitsubishi Tanabe Pharma
• Mylan
• Novartis
• Novo Nordisk
• Nycomed
• Ono Pharmaceutical Co.
• Otsuka Pharmaceutical
• Pfizer
• Procter & Gamble
• Purdue Pharma
• Roche
• Sanofi-Aventis
• Servier
• Shionogi
• Shire
• Takeda
• TEVA
• UCB
• Watson

Contents

• Chapter One: Executive Summary
  • Introduction
  • Scope and Methodology
  • Potential Market Opportunity
  • Issues and Trends Affecting Market
  • Leading Companies
• Chapter Two: Introduction
  • Global Pharmaceutical Market
  • Pharmaceutical Research & Development Overview
  • Clinical Trial Costs
• Chapter Three: Issues And Trends
  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • Pediatric Extensions
  • Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity Legislation
  • Aging Population
  • Mergers, Acquisitions, and Collaborations
  • Contributors To R&D Success
  • R&D Spending
  • The Role of Contract Research Organizations
  • Sustainability in a changing Pharmaceutical Industry
• Chapter Four: Worldwide Pharmaceutical Industry Leaders
  • Introduction
  • Pfizer, Inc./Wyeth (merged in 2009)
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Merck & Co., Inc.
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Novartis AG
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Roche Ltd.
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Sanofi-Aventis
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • AstraZeneca plc
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • GlaxoSmithKline plc
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Johnson & Johnson
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Eli Lilly & Company
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Bristol-Myers Squibb Company
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Abbott Laboratories
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Takeda Pharmaceutical Co., Ltd.
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Bayer AG
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Amgen, Inc.
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Boehringer Ingelheim GmbH
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • TEVA Pharmaceutical Industries, Ltd.
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Astellas
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Daiichi Sankyo
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Novo Nordisk
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
  • Eisai
  • Overview
  • Financial Performance and Investments
  • Late Stage Pipeline
• Chapter Five: Companies Of Interest
  • Introduction
  • Otsuka
  • Late Stage Pipeline
  • Merck KGaA
  • Late Stage Pipeline
  • Gilead Sciences
  • Late Stage Pipeline
  • Mylan
  • Pipeline
  • Baxter International
  • Late Stage Pipeline
  • Chugai Pharmaceutical Company, Ltd.
  • Late Stage Pipeline
  • Mitsubishi Tanabe
  • Late Stage Pipeline
  • Servier, Les Laboratories
  • Pipeline
  • UCB SA
  • Late Stage Pipeline
  • Allergan
  • Late Stage Pipeline
  • Forest Laboratories
  • Late Stage Pipeline
  • Nycomed International
  • Late Stage Pipeline
  • Genzyme Corporation
  • Late Stage Pipeline
  • Biogen Idec
  • Late Stage Pipeline
  • Hospira
  • Late Stage Pipeline
  • Watson
  • Pipeline
  • CSL Limited
  • Late Stage Pipeline
  • Alcon
  • Late Stage Pipeline
  • Shire
  • Late Stage Pipeline
  • Celgene Corporation
  • Late Stage Pipeline
  • Lundbeck
  • Late Stage Pipeline
  • Shionogi & Co., Ltd.
  • Late Stage Pipeline
  • Menarini Group
  • Late Stage Pipeline
  • Dainippon Sumitomo Pharma, Co., Ltd.
  • Late Stage Pipeline
  • Cephalon
  • Late Stage Pipeline
  • Actelion
  • Late Stage Pipeline
  • Procter & Gamble
  • Endo Pharmaceuticals
  • Late Stage Pipeline
  • Ono Pharmaceutical Co.
  • Late Stage Pipeline
  • Purdue Pharma
  • Late Stage Pipeline
• Chapter Six: Market Forecast
  • Overview
  • Company Analysis
  • Pipeline Snapshot: Top 50 Companies
  • Current Market Value
  • Market Forecast
• Chapter Seven: Biopharmaceutical Market
  • Biopharmaceutical Companies
  • Biopharmaceutical Market Forecast
• Appendix: List Of Companies
• Table Of Exhibits
  • Chapter One: Executive Summary
    • Table 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions)
    • Figure 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated
  • Chapter Two: Introduction
    • Table 2-1: Phases of Clinical Drug Development
    • Table 2-2: Components of a Clinical Trial
  • Chapter Three: Issues And Trends
    • Table 3-1: International Population Trend Age 65+
    • Figure 3-1: International Population Trend Age 65+
    • Table 3-2: United States Population Trend Age 65+
    • Figure 3-2: International Population Trend Age 65+
    • Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions
    • Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics
    • Figure 3-3: Drug Development Cost Progression
    • Table 3-5: Total Industry R&D Spending 2004-2009
    • Figure 3-4: Total Industry R&D Spending 2004-2009
  • Chapter Four: Worldwide Pharmaceutical Industry Leaders
    • Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2009 Sales (millions)
    • Table 4-2: Pfizer's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-1: Pfizer's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-3: Pfizer's Late Stage Product Pipeline
    • Figure 4-2: Pfizer's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-4: Merck's* Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-3: Merck's* Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-5: Merck & Co.'s Late Stage Product Pipeline
    • Figure 4-4: Merck's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-6: Novartis' Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-5: Novartis' Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-7: Novartis' Late Stage Product Pipeline
    • Figure 4-6: Novartis' Late Stage Product Pipeline by Therapeutic Area
    • Table 4-8: Roche's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-7: Roche's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-9: Roche's Late Stage Product Pipeline
    • Figure 4-8: Roche's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-10: Sanofi-Aventis' Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-9: Sanofi-Aventis' Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-11: Sanofi-Aventis' Late Stage Product Pipeline
    • Figure 4-10: Sanofi Aventis' Late Stage Product Pipeline by Therapeutic Area
    • Table 4-12: AstraZeneca's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-11: AstraZeneca's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-13: AstraZeneca's Late Stage Product Pipeline
    • Figure 4-12: AstraZeneca' Late Stage Product Pipeline by Therapeutic Area
    • Table 4-14: GlaxoSmithKline's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-13: GlaxoSmithKline's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-15: GlaxoSmithKline's Late Stage Product Pipeline
    • Figure 4-14: GlaxoSmithKline's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-16: Johnson & Johnson's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-15: Johnson & Johnson's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-17: Johnson & Johnson's Late Stage Product Pipeline
    • Figure 4-16: Johnson & Johnson's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-18: Eli Lilly's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-17: Eli Lilly's Total Company Revenue and R&D Spending 2007-2009
    • Table 4-19: Eli Lilly's Late Stage Product Pipeline
    • Figure 4-18: Eli Lilly & Co.'s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-20: Bristol-Myers Squibb's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-19: Bristol-Myers Squibb's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-21: Bristol-Myers Squibb's Late Stage Product Pipeline
    • Figure 4-20: Bristol-Myers' Late Stage Product Pipeline by Therapeutic Area
    • Table 4-22: Abbott's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-21: Abbott's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-23: Abbott's Late Stage Product Pipeline
    • Figure 4-22: Abbott's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-24: Takeda's Total Company Revenue* and R&D Spending 2007-2009 (Millions)
    • Figure 4-23: Takeda's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-25: Takeda Pharmaceutical's Late Stage Product Pipeline
    • Figure 4-24: Takeda Pharmaceutical's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-26: Bayer's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-25: Bayer's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-27: Bayer's Late Stage Product Pipeline
    • Figure 4-26: Bayers' Late Stage Product Pipeline by Therapeutic Area
    • Table 4-28: Amgen's Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-27: Amgen's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-29: Amgen's Late Stage Product Pipeline
    • Figure 4-28: Amgen's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-30: Boehringer Ingelheim's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-29: Boehringer Ingelheim's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-31: Boehringer Ingelheim's Late Stage Product Pipeline
    • Figure 4-30: Boehringer Ingelheim's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-32: TEVA's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-31: TEVA's Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-33: TEVA's Late Stage Product Pipeline Figure 4-32: TEVA's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-34: Astellas' Total Company Revenue and R&D Spending 2007-2009 (millions)
    • Figure 4-33: Astellas' Total Company Revenue and R&D Spending 2007-2009 (millions)
    • Table 4-35: Astellas' Late Stage Product Pipeline
    • Figure 4-34: Astellas' Late Stage Product Pipeline by Therapeutic Area
    • Table 4-36: Daiichi Sankyo's Total Company Revenue and R&D Spending 2007-2009 (millions)
    • Figure 4-35: Daiichi Sankyo's Total Company Revenue and R&D Spending 2007-2009 (millions)
    • Table 4-37: Daiichi Sankyo's Late Stage Product Pipeline
    • Figure 4-36: Daiichi Sankyo's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-38: Novo Nordisk's Total Company Revenue and R&D Spending 2007-2009 (millions)
    • Figure 4-37: Novo Nordisk's Total Company Revenue and R&D Spending 2007-2009 (millions)
    • Table 4-39: Novo Nordisk's Late Stage Product Pipeline
    • Figure 4-38: Novo Nordisk's Late Stage Product Pipeline by Therapeutic Area
    • Table 4-40: Eisai's Total Company Revenue and R&D Spending 2007-2009 (Thousands)
    • Figure 4-39: Eisai's Total Company Revenue and R&D Spending 2007-2009
    • Table 4-41: Eisai's Late Stage Product Pipeline
    • Figure 4-40: Eisai's Late Stage Product Pipeline by Therapeutic Area
  • Chapter Five: Companies Of Interest
    • Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2009 Sales
    • Table 5-2: Otsuka Pharmaceutical's Late Stage Product Pipeline
    • Figure 5-1: Otsuka Pharmaceutical's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-3: Merck KGaA's Late Stage Product Pipeline
    • Figure 5-2: Merck KGaA's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-4: Gilead Sciences' Late Stage Product Pipeline
    • Figure 5-3: Gilead Sciences' Late Stage Product Pipeline by Therapeutic Area
    • Table 5-5: Baxter International's Late Stage Product Pipeline
    • Figure 5-4: Baxter International's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-6: Chugai Pharmaceutical's Late Stage Product Pipeline
    • Figure 5-5: Chugai's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-7: Mitsubishi Tanabe's Late Stage Product Pipeline
    • Figure 5-6: Mitsubishi Tanabe's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-8: UCB Pharma's Late Stage Product Pipeline
    • Figure 5-7: UCB's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-9: Allergan's Late Stage Product Pipeline
    • Figure 5-8: Allergan's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-10: Forest Laboratories' Late Stage Product Pipeline
    • Figure 5-9: Forest Laboratories' Late Stage Product Pipeline by Therapeutic Area
    • Table 5-11: Nycomed's Late Stage Product Pipeline
    • Figure 5-10: Nycomed's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-12: Genzyme's Late Stage Product Pipeline
    • Figure 5-11: Genzyme's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-13: Biogen Idec's Late Stage Product Pipeline
    • Figure 5-12: Biogen Idec's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-14: Hospira's Late Stage Product Pipeline
    • Figure 5-13: Hospira's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-15: CSL's Late Stage Product Pipeline
    • Figure 5-14: CSL's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-16: Alcon's Late Stage Product Pipeline
    • Figure 5-15: Alcon's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-17: Shire's Late Stage Product Pipeline
    • Figure 5-16: Shire's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-18: Celgene's Late Stage Product Pipeline
    • Figure 5-17: Celgene's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-19: Lundbeck's Late Stage Product Pipeline
    • Figure 5-18: Lundbeck's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-20: Shionogi's Late Stage Product Pipeline
    • Figure 5-19: Shionogi's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-21: Menarini's Late Stage Product Pipeline
    • Figure 5-20: Menarini's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-22: Dainippon Sumitomo's Late Stage Product Pipeline
    • Figure 5-21: Dainippon Sumitomo's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-23: Cephalon's Late Stage Product Pipeline
    • Figure 5-22: Cephalon's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-24: Actelion's Late Stage Product Pipeline
    • Figure 5-23: Actelion's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-25: Endo Pharmaceutical's Late Stage Product Pipeline
    • Figure 5-24: Endo Pharmaceutical's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-26: Ono Pharmaceutical's Late Stage Product Pipeline
    • Figure 5-25: Ono Pharmaceutical's Late Stage Product Pipeline by Therapeutic Area
    • Table 5-27: Purdue Pharma's Late Stage Product Pipeline
    • Figure 5-26: Purdue Pharma's Late Stage Product Pipeline by Therapeutic Area
  • Chapter Six: Market Forecast
    • Table 6-1: Top Pharmaceutical Companies, 1-50 by 2009 Sales (millions)
    • Table 6-2: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
    • Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
    • Table 6-3: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)
    • Figure 6-2: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)
    • Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010 ($ in billions)
    • Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment 2005-2010
    • Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions)
    • Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated
    • Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—Potential Impact from Late-Stage Development
    • Figure 6-6: Global Pharmaceutical Market Forecast by, 2015—Potential Impact from Late-Stage Development
  • Chapter Seven: Biopharmaceutical Market
    • Table 7-1: Top 10 Biotechnology Companies*, 2009 Sales
    • Table 7-2: Top 10 Biotechnology and Pharmaceutical Products, by 2009 Revenues
    • Table 7-3: Biotechnology Late Stage Development Projects by Company Classification—Pharmaceutical vs. Biotechnology--Market Forecast, 2015

Related products

Latest Chinese Regulations for Imported Drug Registration China Pharmaceutical Guidebook China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2006, sales on the Chinese drug market have reached $12...

Strategies for Innovation in Pharmaceutical R&D Enhancing R&D Through Biotech Alliances and CRO Outsourcing This new report has been written to provide members of pharmaceutical, biotechnology and clinical research sectors an analytically-based overview of the mechanisms of the partnering process, and the key issues...

Global and China Biopharmaceutical Industry Report 2010 In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound annual growth rate of biopharmaceutical industry reached 18.6%,...

Research Report on China's Biopharmaceutical Industry, 2009 In 2008, the market size of China's biopharmaceutical industry was about 70 billion Yuan (about 10 billion US Dollars), whose growth rate passed the whole market size of China's medicine...

New Developments in Treating Genetic Disorders: The Global Market Study Goals and Objectives The Goal of The Study, New Developments in Treating Genetic Disorders: The Global Market, Is to Provide An Overview of A Range of Genetic Disorders, Both...

Biosimilars 2009 - 2014 The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars...

Technology Transfer Strategies A Guide to Maximizing Returns within The Pharmaceutical and Biopharmaceutical Industries Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries Summary GBI Research, the leading business intelligence provider, has released its latest research, "Technology Transfer Strategies -...

Fastest Growing Biotechnology Companies, The Growth Strategies, Comparative Analyses and Company Profiles In recent years, the biopharmaceutical industry has emerged as one of the most important sectors in the Healthcare field. Advances in life sciences have resulted in the drug discovery process...

Global Market: Biopharmaceuticals Market Trends & Competition Today’s pharmaceutical industry is shifting toward biopharmaceuticals at a drastic speed. In 2009, sales of biopharmaceutical drugs accounted for 13% of the total sales of pharmaceuticals.  And today, biopharmaceuticals account for 25% of all...

Small and Medium Biopharmaceutical Enterprises in North America and Europe Biotechnology Clusters, Funding Characteristics and Regulatory Landscape GBI Research, the leading business intelligence provider, has released its latest research, "Small and Medium Biopharmaceutical Enterprises in North America and Europe - Biotech Clusters, Funding Characteristics and Regulatory Landscape."...

Respiratory Therapeutics and Devices Markets In the respiratory therapeutics and devices market, continuing new advancements in the ability to detect and manage respiratory diseases are being made. The respiratory disease space is one of the...

Chinese Biopharmaceutical Industry Current State and Future Development The development of biologic drugs has gradually become the key focus of all drug companies worldwide, large or small, major or startup. Major pharma companies, which used to almost...

Pharmaceutical Outsourcing Opportunities Post-Launch: Contract Manufacturing and Contract Sales and Marketing 3rd Edition This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for...

Global Pharmaceutical Biotech Market 2010-2025 Market growth, novel technologies and expansion into new therapeutic areas The global pharmaceutical biotech market continues to experience high growth, with developers ranging from major pharmaceutical companies to specialist pharmaceutical firms. Significant R&D efforts and innovative new treatments will lead...

Research Report on China's Biopharmaceutical Industry 2010-2012 In China, biological products for human use include bacterial vaccines (including toxoid), viral vaccines, antitoxin and immune serum, blood products, cytokines, in vivo and in vitro diagnostic products and other...

Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics This Report: Discussion of Treatment Options, Key Products and New Developments in Therapies for Such Genetic Disorders as Cystic Fibrosis, Gaucher Disease, Hemophilia, Huntington' S Disease, Sickle-Cell Disease, and Tay-Sachs Disease Analysis...

Advances in Biopharmaceutical Technology in China Advances in Biopharmaceutical Technology in China, September 2006, ISBN 1-934106-00-3 ~1210 pages; This volume provides an overview of the biopharmaceutical industry, and the state of technology in China. ...

Delivering New Biopharmaceutical Therapies Challenges & Opportunities This cutting edge & insightful report can be used to interpret & assess the potential of new biopharmaceuticals. It provides opinions & market projections to: gain an in-depth understanding of...

Contract Pharma 2008-2023 The revenue for world contract manufacturing business in 2007 was approximately $30bn, with a growth rate of 6% from 2006. The technical expertise and cost savings offered by contract manufacturing...

China Pharmaceutical Industry Report (Merger and Reorganization), 2006-2007 During the Tenth Five-Year Plan period (2001 to 2005), each indicator of the whole pharmaceutical industry greatly exceeded the scheduled; and the industrial output value, industrial added value and total...

What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 The future of the pharmaceutical market will be determined by biologics - drugs produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms...

Biosimilars: Surveying the Market Landscape Worldwide, the story is the same. Governments want cheaper drugs for their populations, while the number and kinds of diseases affecting them continue to evolve and grow. Since 1976, when Genentech...

World Biological Drugs Market 2011-2021 Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide...

Biopharmaceuticals A Global Market Overview Intense research efforts made biopharmaceuticals the most successful products in various therapeutic areas such as Neurology, Infectious Diseases, Cardiovascular, Oncology etc. Undoubtedly, all the major pharmaceuticals are, now, engaged in...

A Practical Guide to Biopharmaceutical Manufacturing The first version of this aid to understanding pharmaceutical R&D was published in 2003 and updated in 2005. It concentrated on small molecule drugs (molecular weights usually below 500 daltons)...

China Biopharmaceutical Industry Report, 2006-2007 In 2006, under the influences of drug depreciation, publishing commercial bribery and the rise in raw material cost, the growth in manufacturing and sales of China pharmaceutical industry slowed down...

Canada Pharmaceutical Industry The Canadian pharmaceutical market is the eighth largest in the world, accounting for about two percent of the world market by sales. Canada also has the fourth fastest growing pharmaceutical...

View all products in this category